Aptahem AB (XSAT:APTA) Total Liabilities: kr1.42 Mil (As of Mar. 2026)


XSAT:APTA Aptahem AB XSAT:APTA
30 GF Score
Price kr0.60
! 2 Warning Signs
View Full Analysis

What is Aptahem AB Total Liabilities?

Aptahem AB XSAT:APTA +2.74% 30 Total Liabilities is kr1.42 Mil as of Mar. 2026. GuruFocus rates XSAT:APTA with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Aptahem AB's Total Liabilities for the quarter that ended in Mar. 2026 was kr1.42 Mil.

Aptahem AB's quarterly Total Liabilities declined from Sep. 2025 (kr1.74 Mil) to Dec. 2025 (kr1.16 Mil) but then increased from Dec. 2025 (kr1.16 Mil) to Mar. 2026 (kr1.42 Mil).

Aptahem AB's annual Total Liabilities declined from Dec. 2023 (kr9.00 Mil) to Dec. 2024 (kr2.60 Mil) and declined from Dec. 2024 (kr2.60 Mil) to Dec. 2025 (kr1.16 Mil).

Aptahem AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for Aptahem AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aptahem AB Total Liabilities Chart

Aptahem AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.27 9.45 9.00 2.60 1.16

Aptahem AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.63 1.45 1.74 1.16 1.42
XSAT:APTA
30GF Score
Aptahem AB XSAT:APTA
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aptahem AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Aptahem AB's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.159+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.16

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=68.53-67.371
=1.16

Aptahem AB's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.424+(0+-0.00099999999999989
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.42

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=67.401-65.978
=1.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of kr1.42 Mil mean?
Aptahem AB (XSAT:APTA) has a Total Liabilities of kr1.42 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Aptahem AB and its competitors.
Is Aptahem AB's Total Liabilities too high?
Aptahem AB's current Total Liabilities is kr1.42 Mil. Overall, Aptahem AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Aptahem AB's Total Liabilities compare to VRTX and REGN?
Aptahem AB's Total Liabilities of kr1.42 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Aptahem AB and its competitors. Aptahem AB's current Total Liabilities is kr1.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptahem AB stock overvalued right now?
Aptahem AB (XSAT:APTA) has a current Total Liabilities of kr1.42 Mil. The current Total Liabilities is kr1.42 Mil. Aptahem AB's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Aptahem AB (XSAT:APTA), the current Total Liabilities is kr1.42 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aptahem AB Business Description

Address Norra Vallgatan 58, Malmo, SWE, 211 22
Aptahem AB develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's main candidate Apta-1 is developed as an emergency medicine intended to prevent the occurrence of life-threatening organ and tissue damage in patients suffering from sepsis.
30GF Score

Get the complete analysis for XSAT:APTA

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.60
Price